Immutep Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMP research report →
Range $3.5 – $5
Price Chart
About the company
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
- CEO
- Marc Voigt
- IPO
- 2012
- Employees
- 53
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on IMMP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.92M
- P/E
- -0.45
- PEG
- 0.01
- P/S
- 2.43
- P/B
- 0.57
- EV/EBITDA
- 0.38
- Div Yield
- 0.00%
- Gross Margin
- 84.97%
- Op Margin
- -597.44%
- Net Margin
- -544.79%
- ROE
- -98.86%
- ROIC
- -125.32%
Latest fiscal year · YoY change
- Revenue
- $14.24M+182.3%
- Gross Profit
- $11.82M+121.0%
- Op Income
- $-82,045,817
- Net Income
- $-77,571,656-26.3%
- EPS
- $-10.70-26.8%
- OCF Growth
- +12.6%
- FCF Growth
- +12.5%
- 52W High
- $70.60
- 52W Low
- $2.66
- 50D MA
- $4.11
- 200D MA
- $13.07
- Beta
- 2.37
- RSI (14)
- 47
- Avg Volume
- 25.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Management said the company is expanding U.S. investor outreach, preparing broader ICS data from 63 patients, and planning CANVAS with up to 120 patients across as many as 80 targeted centers.· August 5, 2013
- ICS readout will be based on a larger dataset: baseline-to-dosing immune responses across all 63 patients, not just the small snapshot shown last year.
- Prima thinks increased NASDAQ trading reflects more U.S. investor engagement, a hotter biotech market, and growing interest in immune therapy after ASCO.
- Foreign exchange risk is partly cushioned by euro and U.S. dollar holdings, and the company says it also has hedging contracts tied to projected operations.
- For CANVAS, the protocol allows up to 120 patients and management is targeting about 80 centers, with roughly 50 of those as core clinical centers.
- Management expects recruitment to vary widely by site, from about half a patient to about one patient per center per month depending on geography and referral strength.
No revenue, EPS, gross margin, or other hard financial results were reported in this Q&A-only transcript. Management did discuss cash-related foreign exchange exposure: Marc Voigt said the company holds significant euro and U.S. dollar balances, and reported a foreign exchange gain of about $1.4 million to $1.5 million in the report. On guidance, management said the ICS work is now focused on baseline-through-dosing immune profiles across all 63 patients, and CANVAS is being planned with up to 120 patients, about 80 targeted centers, and roughly 50 core clinical centers; recruitment may range from half a patient to one patient per center per month depending on the site.
Matthew Lehman’s tone was upbeat but measured. He emphasized that the company is spending more time in the U.S. educating investors, that the story around immune therapy is resonating, and that the recent increase in trading activity is a positive sign of growing interest on both the Australian and U.S. exchanges. On publicity and messaging, he said Prima wants to get its story out, but also does not want to over-communicate or get ahead of the clinical data.
Marc Voigt addressed foreign exchange and liquidity positioning. He said Prima holds significant euro and U.S. dollar balances, which helps buffer the weaker Australian dollar, and that the company has hedging contracts based on projected ongoing operations. He also said this currency mix is favorable because most clinical operations run in Europe and the United States, reducing exposure to Australian-dollar weakness.
The main clinical question was about the upcoming ICS test results and whether they would match last year’s release. Sharron Gargosky said this year’s analysis is broader and more informative because it includes longitudinal data from baseline through the dosing period across all 63 patients, rather than last year’s small snapshot of five CVac patients and a couple of standard-of-care patients. Another question focused on the recent increase in Prima shares trading on NASDAQ; Lehman said he did not know of a specific catalyst and attributed it mainly to increased U.S. outreach, a stronger biotech market, and rising scientific and financial interest in immune therapy.
The call suggested the company may have several visible catalysts: broader ICS data, a larger CANVAS clinical footprint, and increasing investor attention in the U.S. Management sounded encouraged by the interest in immune therapy and by the idea that a larger dataset could better show treatment response over time. Currency positioning also appears relatively protected, with euro and U.S. dollar cash balances and hedging in place.
Management did not provide any hard operating or financial performance numbers in this exchange, leaving investors without near-term results to assess. Recruitment for CANVAS sounds operationally complex and center-dependent, and management acknowledged that patient enrollment can be slow because patients are being approached soon after an ovarian cancer diagnosis and before chemotherapy. The company also said it is proceeding cautiously on publicity and on how it presents trial data, which implies the program is still early and data-dependent.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.1%
- Shares Outstanding
- 7.37M
- Float Shares
- 7.15M
of shares held by institutions
28 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Personalized Indexing Management, LLC | 358.69K | ▲ 358.69K |
| Two Sigma Investments, LP | 77.13K | ▼ 47.63K |
| Susquehanna International Group, Llp | 27.73K | ▲ 27.73K |
| Virtu Financial LLC | 22.72K | ▼ 18.64K |
| Tower Research Capital LLC (Trc) | 10.12K | ▼ 5.68K |
| Cva Family Office, LLC | 2.65K | ▲ 2.65K |
Held by 3 ETFs
Biggest fund positions in IMMP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Boyce Elisabeth Amanda | other | 0 |
| Dec 1, 28 | Boyce Elisabeth Amanda | other | 0 |
| Dec 1, 26 | Boyce Elisabeth Amanda | other | 0 |
| Dec 1, 26 | Boyce Elisabeth Amanda | other | 0 |
| Mar 18, 26 | Voigt Marc | other | 0 |
| Dec 1, 28 | Voigt Marc | other | 0 |
| Mar 18, 26 | Voigt Marc | other | 0 |
| Mar 18, 26 | Voigt Marc | other | 0 |
| Mar 18, 26 | Miller Deanne Diem | other | 0 |
| Dec 1, 28 | Miller Deanne Diem | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMMP coverage
Recent articles, reports, and earnings notes.
No research on IMMP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMP report →Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial
benzinga.com · Nov 19
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
globenewswire.com · Nov 18
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
globenewswire.com · Nov 10
Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
globenewswire.com · Nov 10
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
globenewswire.com · Nov 8
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
globenewswire.com · Nov 5
Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average – What’s Next?
defenseworld.net · Oct 20
Immutep Receives ~A$0.86 Million R&D Tax Incentive
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.